美股異動丨禾賽盤前漲超5.8% 首季激光雷達交付量同比大增231.3%
禾賽(HSAI.US)盤前漲超5.8%,報22.7美元。消息面上,禾賽第一季度實現營收5.3億元,同比增長46.3%;GAAP淨虧損同比大幅收窄84%至1750萬元,並實現Non-GAAP盈利,表現出超出市場預期的增長動能,穩步邁向全年盈利目標。期內激光雷達總交付量達195,818臺,同比增長231.3%,延續高速增長態勢。其中,ADAS產品交付量爲146,087臺,同比增長178.5%;機器人領域產品交付量爲49,731臺,同比增長649.1%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.